The ubiquitous transcription factor, NF-κB, has been reported to inhibit apoptosis and induce drug resistance in cancer cells. Cordyceps militaris extract (CME) is involved in the regulation of the NF-κB signaling pathway. However, the detailed role of CME in the suppression of the NF-κB signaling pathway is unclear. We found that CME dose-dependently inhibited tumor necrosis factor-α (TNF-α)-induced NF-κB activation in TK-10 human renal cell carcinoma. CME prevented NF-κB from translocating to the nucleus, which resulted in the downregulation of GADD45B, upregulation of MKK7, and phosphorylation of JNK (p-JNK). The increased activation of Bax led to pronounced CME-induced apoptosis, which occurred through caspase-3. Furthermore, the siRNAmediated knockdown of GADD45B inhibited MKK7 expression, whereas the siRNA-mediated inhibition of MKK7 downregulated p-JNK and the JNK inhibitor, SP600125, inhibited Bax expression. Thus, these results indicated that CME inhibited the activation of GADD45B via the inhibition of NF-κB activation, which upregulated the MKK7-JNK signaling pathway to induce apoptosis in TK-10 cells. Thus, this study reveals a novel anticancer function of CME.
Cordyceps militaris is a genus of parasitic fungi. The extract of Cordyceps militaris (CME) has traditionally been used as an herbal medicine in Korea and China to enhance longevity and vitality [1, 2] . Several of the well-known active ingredients of these mushrooms include cordycepin, cordycepic acid, sterols (ergosterol), nucleosides, and polysaccharides [3] . CME has been reported to exert immunomodulatory, anti-inflammatory, antimicrobial, Anti-adipogenic and antitumor effects, although the primary pharmacological activity may vary slightly depending on the main ingredients of the extract [4, 5] . Evidence from both in vivo and in vitro experiments has demonstrated the anti-proliferative and apoptotic activities of CME in human tumor cell lines, including H460, RKO, PC-3, MDA-MB 231, and HepG2. The main antitumor effects of CME occur through the induction of apoptosis in tumor cells, inhibition of angiogenesis, and suppression of invasion and metastasis [6] [7] [8] [9] . Consequently, CME has received considerable global attention as a potential source of anticancer drugs [10] .
The NF-κB family of transcription factors has an essential role in inflammation and innate immunity. Furthermore, there are reports of NF-κB as a crucial player in many steps of cancer initiation and progression [11] . The NF-κB family of transcription factors is protein complexes that act as signal-induced transcription factors. In cancer cells, NF-κB has emerged as a critical component in many steps of cancer initiation and progression [11] . IκB kinase (IKK) mediates phosphorylation of inhibitory molecules, which is essential for NF-kB activation [12] . After phosphorylation by the IKK complex, IB is rapidly ubiquitinated and degraded by the 26S proteasome, which releases the NF-B subunits and then causes translocation to the nucleus [13] . Thus, the blockade of NF-B signaling may be induced either by inhibition of proteasometriggered degradation by proteasome inhibitors or several natural products and drugs with anticancer and anti-inflammatory activities [14] . In addition, NF-B countersprogrammed cell death (PCD) induced by the proinflammatory cytokine TNF-α [15] . With regard to TNF-, the NF-B-mediated inhibition of PCD appears to involve attenuation of the c-Jun-N-terminal kinase (JNK) cascade mediated through the induction of selected downstream targets, such as the caspase inhibitor XIAP, the zinc-finger protein A20, and the inhibitor of the MKK7/JNKK2 kinase, GADD45B/Myd118 [16] . JNKs belong to the MAP-kinase superfamily involved in the regulation of cell growth, differentiation, and PCD [17] . In addition to the possibility that the JNKs can directly induce both apoptosis and growth, it is also possible that a compensatory proliferation of the neighboring cells might be an essential linker to bridge apoptosis and carcinogenesis [18] .
The cytotoxicity of CME in TK-10 cells was performed by cell counting kit-8 assay. The cells were treated directly with CME at 0, 0.5, 1, 1.5, and 2 mg/mL for 48 h. As shown in Figure 1A , CME dose-dependently inhibited the growth of TK-10 cells over incubation for 48 h. At 1 mg/mL, CME inhibited approximately half of the TK-10 cell population. The half-maximal inhibitory concentration (IC 50 ) was determined as 1 mg/mL CME. Additionally, we evaluated CME-induced apoptosis in TK-10 cells by flow cytometric analysis of annexin V-and PI-stained cells. However, 0.5 mg/mL CME caused no drastic fluctuations in the annexin V-stained viable fraction of TK-10 cells (95 % to 84 %) ( Figure 1B ).
However, 1 mg/mL treatment of CME was significantly shifted from the normal state to the late apoptotic stage (3 % to 14 %), whereas the viable fraction was reduced from 95 % to 61 %. The induction of apoptosis by CME increased in a dose-dependent manner. Collectively, the results showed that CME treatment induced apoptotic death in TK-10 renal cancer cells.
Various properties of CME have been reported, including antitumor, antiviral, anti-oxidant, and anti-inflammatory activities [19] . Several reports over the past few years have shown that cordycepin, a major active ingredient of CME, inhibits the expression of inflammatory genes via the suppression of NF-κB activation [20] . For example, cordycepin suppresses the expression of IL-1β, TNF-α, IL-6, ICAM-1, and VCAM-1 [21] . Meanwhile, other investigations have indicated that the anticancer and antimetastatic effects of cordycepin are realized by an inhibition of the levels of certain critical molecules involved in tumor growth and metastasis through the blocking of NF-κB activation [22] and the PKC, MAPK, JNK, caspase-7, and PARP pathways [23] . These previous studies suggested that cordycepin is involved in the regulation of the NF-κB signaling pathway.
To confirm the genes involved in the anticancer activity of CME, a microarray analysis of CME-treated TK-10 cells was conducted. The microarray data have been submitted to the Gene Expression Omnibus database (GEO accession number GSE81728). Among the 63,242 unique genes tested (Agilent Human GE 8×60K Microarray), 30,858 genes were expressed in the cells. Among these 30,858 genes, 143 and 219 genes were upregulated and downregulated, respectively, by treatment with 1 mg/mL CME at 48 h, compared with those in the untreated cells. Biologically relevant features were constructed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) tools (http://david.abcc.ncifcrf.gov/). The lists of genes that showed twofold up-and downregulation in the CME-or -induced renal cancer cells were uploaded to DAVID for Gene Ontology analysis ( Figure  2A) . To compare the results in terms of the genes potentially involved in apoptosis (https://www.ncbi.nlm.nih.gov/gene), we independently evaluated the association between apoptosis and genes whose expression was changed by more than two-fold in (D) Signaling network of the apoptotic genes in response to CME. Nodes colored by using IPA are the genes in the apoptotic regulatory network in CME-treated TK-10 cells (red: upregulated genes, green: downregulated genes). CME-treated cells compared with those in the untreated cells ( Figure 2B ). The intersection obtained by hierarchical clustering is presented along with the gene lists in Figure 2C . The signal network of apoptotic genes in response to CME is shown in Figure 2D . In the signal network, the expression of the ANGPTL, which inhibits cancer cell migration and metastasis, was increased by CME treatment. Additionally, the expression of CCL-2 and CCL-3, which stimulate cancer cell migration and GADD45B, which are usually reduced by an increase in NF-κB activation, was decreased by CME treatment in TK-10 cells. NF-κB is a transcription factor with a crucial role in cytokine-and TNF--induced gene activation during inflammatory events [24] . The incubation of TK-10 cells with NO donors inhibits TNF--induced NF-κB activation through the induction and stabilization of the NF-κB inhibitor IκB [25] .To investigate the effect of CME on the NF-κB signaling pathway, western blotting analysis was performed to detect the expression of IκB, NF-κB, GADD45B, MKK7, Bax, caspase-3, and cleaved caspase-3 in TK-10 cells cultured in 0.5 and 1 mg/mL CME. CME reduced NF-κB, IB, and GADD45B expression, but dosedependently increased MKK7, Bax, and cleaved caspase-3 expression ( Figure 3A) . Next, we confirmed whether CME inhibited nitric oxide (NO) production induced by TNF-α treatment, which is a well-known NO inducer. The pre-treatment with CME significantly blocked NO production in TK-10 cells ( Figure 3B ). The effect of CME on NF-κB promoter activation in TK-10 cells was measured by luminometry after the 3x-kB plasmid was transfected into the cells for 4 h. The incubation with CME at 0.5, 1, and 1.5 mg/mL significantly decreased the NF-κB activity to 14% and 51% of the control activity, respectively ( Figure 3C ).Under unstimulated conditions, NF-κB (RelA or p65) is retained in the cytoplasm by a set of inhibitory proteins, IκB. When the cytokine TNF-α binds to the TNF receptor, IκB dissociates from NF-κB [26] . As a result, the active NF-κB translocates to the nucleus. Green fluorescently-tagged p65 was localized to the cytoplasm of the untreated cells. CME treatment significantly reduced TNF-α-induced NF-κB (p65) translocation to the nucleus. When TK-10 cells were stimulated with TNF-α, p65 translocated to the nucleus. Modulation of the NF-kB signaling pathway by CME. (A) CME inhibits the IκB/NF-κB signaling pathway. Western blotting was performed for NF-κB, GADD45B, MKK7, Bax, caspase-3, and cleaved caspase-3 in CME-treated TK-10 cells. (B) CME inhibited TNF-α-induced stimulation of NO. (C) Estimation of NF-κB promoter activity in TK-10 cells by luciferase assay. Luciferase activity was determined through the measurement of the luminescence levels of both firefly and Renilla luciferase with a luminometer. **p < 0.01 and ***p < 0.001. (D) Effects of CME on TNF-α-induced nuclear translocation of NF-κB p65 in TK-10 cells. NF-κB p65 localization was visualized by fluorescence microscopy after immunofluorescence staining with NF-κB p65 antibody (green). To visualize the nuclei (blue), the cells were stained with DAPI. A representative sample of three independent experiments is shown.
Incubation with CME (0.5 and 1 mg/mL) prevented the translocation of p65 to the nucleus, resulting in its retention in the cytoplasm ( Figure 3D ). In summary, CME treatment attenuated NF-κB signaling in TNF-α-treated TK-10 cells and also blocked the NO production-mediated IB/NF-κB response.
To investigate whether CME induces MKK7 activation through the suppression of NF-κB, we determined the effect of GADD45B on MKK7 in CME-treated TK-10 cells. CME promoted MKK7 expression, but decreased GADD45B and NF-κB levels. Although the treatment of cells with siRNA to GADD45B induced MKK7 expression, the expression of MKK7 was much more clearly induced by CME co-treatment, although NF-κB expression was unaffected ( Figure 4A ). These results indicated that CME mediated the increase in MKK7 expression via the inhibition of GADD45B expression. Moreover, GADD45B inhibits JNK activation through the reduction of apoptosis of TK-10 cells. Thus, we investigated whether GADD45B mediates anti-apoptotic crosstalk between the NF-κB and JNK pathways in CME-treated TK-10 cells. Western blotting analysis was performed to detect the expression of NF-κB, GADD45B, MKK7, p-JNK, and JNK in TK-10 cells cultured in 1 mg/mL of CME. CME treatment downregulated NF-κB, GADD45B expression, but increased MKK7 and p-JNK levels. The siRNA-mediated knockdown of MKK7 decreased p-JNK levels, but did not change NF-κB and GADD45B expression ( Figure 4B ). Additionally, the apoptotic effect of CME through MKK7 signaling was detected by migration assay. Although CME treatment blocked cell proliferation, the co-treatment with MKK7 siRNA and CME triggered cancer cell growth ( Figure 4C ).To further investigate whether the regulation of Bax expression by JNK after CME treatment was related to NF-κB-GADD45B, we examined the expression of Bax protein after CME treatment. The effects of JNK on Bax expression in TK-10 cells exposed to CME in the presence of the JNK inhibitor SP600125 were also observed. CME treatment in TK-10 cells upregulated p-JNK, Bax, cleaved caspase-3, and cleaved PARP-1 expression, whereas co-treatment with the JNKspecific inhibitor SP600125 resulted in decreased p-JNK, Bax, cleaved caspase-3, and cleaved PARP expression ( Figure 5 ). The knockdown of MKK7 significantly decreased p-JNK levels, but did not alter the expression of NF-κB and GADD45B. These results indicated that CME mediates the MKK7's apoptotic regulation of JNK through the downregulation of NF-κB-GADD45B signaling. This implies that CME can regulate aspects of transcriptional responses.
Comparison of CME composition depending on extraction solution: Triple Quadrupole LC/MS (ESI) analysis was conducted to quantify the composition of CME. Table 1 shows the comparison of the quality of CME, as determined using a high-resolution mass spectrometer and traditional medicine library. Many of the compounds were nucleotides and cordycepin. Q-TOF mass spectrometry analysis was the amount of cordycepin in the 50 % methanol/water solution. The 50 % methanol extract has 10-fold more cordycepin than the water extract in the range of 2-3 min.
Q-TOF mass spectrometry and spectral interpretation for sample qualification: The LC separation was performed using an Acquity I-Class UPLC (Waters, Manchester, UK) with an Acquity UPLC BEH C18 column (1.7 µm, 2.1×100 mm). The column temperature was 40°C. Mobile phase A was water with 0.1 % formic acid and mobile phase B was acetonitrile with 0.1 % formic acid. The injection volume was 2 µL and the flow rate was set at 0.4 µL/min. The MS detection was performed on SYNAPT G2-Si system (Waters, Manchester, UK). The data acquisition mode was MSE. The ionization modes of ESI-positive and negative were used. The source and reservation temperatures were set at 120°C and 300°C, respectively. The lock mass compound used was leucine enkephaline (556.2771 in positive, 554.2615 in negative) as the external standard. The following operation parameters were used: ESI positive capillary voltage was set at 3 kV and negative was set at 2.5 kV; cone voltage was set at 30 V. The collision energies were set as a6 eV ramp (trap) for the low energy scan and a 20-45 eV ramp (trap) for the high energy scan. The scan mass range was 100-1500 m/z. The LC-MS data acquisition was controlled by MassLynx 4.1 Waters, Manchester, UK). The acquisition data processing was performed by UNIFI1.8 with traditional medicine library. Table 1 : Quantification of CME compositions, using high-resolution mass spectrometer and traditional medicine library.
Figure 6: Quality evaluation of CME, using a high-resolution mass spectrometer and a traditional medicine library (up: ESI-Positive, down.: ESI-Negative)
